BMO Capital analyst Kostas Biliouris has maintained their bullish stance on TRML stock, giving a Buy rating yesterday.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight the potential of Tourmaline Bio’s lead product candidate, Pacibekitug. A critical upcoming event is the CKD data release in the second quarter of 2025, which is expected to provide insights into Pacibekitug’s efficacy and regimen superiority over its main competitor, Ziltivekimab. This data could position Pacibekitug as a best-in-class treatment in a substantial market with over 20 million patients in the US, potentially leading to significant partnership interest and a notable increase in Tourmaline Bio’s stock value.
Moreover, the management’s projections based on previous data suggest that Pacibekitug could offer superior efficacy and less frequent dosing compared to its competitors. The safety profile is also promising, with no infection concerns observed in previous trials. Additionally, the anticipated cardiovascular outcomes trial (CVOT) results for Ziltivekimab in late 2025 or early 2026 could further validate the relationship between hs-CRP and cardiovascular disease, potentially driving a 50-100% upside in Tourmaline Bio’s stock. These factors collectively contribute to the Buy rating by Kostas Biliouris.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.